Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Amyotrophic Lateral Sclerosis
- Sponsor
- University of Miami
- Enrollment
- 700
- Locations
- 15
- Primary Endpoint
- Genetic determinants of phenotype
- Status
- Enrolling By Invitation
- Last Updated
- 10 months ago
Overview
Brief Summary
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA), and frontotemporal dementia (FTD); and (2) to develop biomarkers that might be useful in aiding therapy development for this group of disorders.
Detailed Description
This study will recruit patients with ALS, ALS-FTD, PLS, HSP, and PMA, with a focus on incident cases. Patients with both familial and sporadic forms of these diseases will be enrolled and followed longitudinally using a standardized set of evaluations. Biological samples (blood, urine, CSF) will be collected from all study participants, and will be used for biomarker discovery and validation. Family members of affected individuals may also be enrolled and asked to contribute DNA and biological samples to aid genetic and biomarker discovery.
Investigators
Michael Benatar
Chief of the Neuromuscular Division, Professor of Neurology
University of Miami
Eligibility Criteria
Inclusion Criteria
- •Member of at least one of the following categories:
- •Individuals with a clinical diagnosis of ALS or a related disorder, including FTD, HSP, PLS, PMA and MSP (sporadic or familial).
- •Family member of an enrolled affected individual.
- •Able and willing to comply with relevant procedures.
Exclusion Criteria
- •Affected with end or late stage disease.
- •A condition or situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol. This includes (but is not limited to) neurological, psychological and/or medical conditions.
Outcomes
Primary Outcomes
Genetic determinants of phenotype
Time Frame: 24 months
By combining longitudinally collected deep phenotypic data with deep genetic data (e.g. whole exome or whole genome sequencing), this project aims to define genetic variants that are associated with identifiable phenotypic features in patients with ALS and related disorders.
Phenotypic correlates of genotype
Time Frame: 24 months
Using longitudinally collected deep phenotypic data, this project aims to define the natural history (i.e. temporal rate of disease progression) of the motor and frontotemporal system (behavior, cognition and language) phenotypes of ALS and related disorders in patients with identifiable genetic mutations.